Biocon Biologics Limited has sold its Indian branded formulations business to Eris Lifesciences Limited for an aggregate consideration of ₹1,242 Crore.
As part of this deal, Biocon Biologics Limited also signed a 10-year supply agreement with Eris Lifesciences Limited.
JSA assisted Biocon in navigating complex legal issues, including those under Indian pharmaceutical regulations, intellectual property laws and tax laws, each of which had material commercial implications for the transaction. The team helped the client balance various commercial considerations while structuring the deal and helped parties enter this long-term collaboration seamlessly.
The transaction team consisted of Probir Roy Chowdhury (Lead Partner), Yajas Setlur (Partner), Soumya Bhargava (Senior Associate), Moushami Nayak (Associate) and Nikhil George (Associate).
This collaboration is in-line with Biocon Biologics’ strategy to unlock value from its legacy business of branded formulations built over the past two decades and extends its existing partnership with Eris for Biocon’s Nephrology and Dermatology business announced in December 2023.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.